NMI TT Pharmaservices Establishes New Branch in Berlin
News Sep 22, 2015
NMI TT Pharmaservices has announced that it is growing its operations by establishing a new branch at the Bayer HealthCare CoLaborator in Berlin.
The new outstation is located on the Bayer HealthCare campus, within the CoLaborator building that is rented out by Bayer to smaller companies and start-ups. NMI TT Pharmaservices will be using the new and already functional laboratory space to provide life science researchers with its proprietary DigiWest multiplex protein profiling services, to accelerate lead characterization, disease mechanism and drug mode-of-action analyses as well as biomarker identification projects for industrial clients and academic partners alike.
In addition, the new office will play a key role for advancing NMI TT Pharmaservices’ market positioning by expanding its business activities beyond the existing well-established customer base.
“We are very excited to start this new phase in our company’s development,” commented Prof. Dr. Hugo Hämmerle, CEO of NMI TT GmbH. “We see our expansion to Berlin as a unique opportunity to intensify our business development efforts across the international pharma and biotech market. This move also happens at a particularly promising time in the development of the proteomics field, which we are keen to help drive forward in the years to come, now through both our Reutlingen team and our new Berlin unit.”
“The chances of this new endeavour are manifold,” added Dr. Christoph Sachse, Site Head of the NMI TT Berlin operation. “We expect that being closer to the needs of pharma R&D scientists and the lively Berlin biotech community will substantially help us in further developing and in marketing our wide range of contract research offerings, in particular our multiplex protein profiling platform, but also our capabilities in cellular assays and in generating customized cell lines.”
As a part of the inauguration, a symposium entitled “Protein Biomarkers: Technologies and Applications”, jointly organized by NMI TT Pharmaservices and Bayer HealthCare, is being held today at the CoLaborator in Berlin. The symposium will serve as a forum to foster mutually beneficial scientific discussions between scientists of the two organizations, together with international experts in the field and numerous guests from Berlin’s research community.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Key to Creating Better Medicines with Less Side EffectsNews
A new study published in Science by Professors Yossi Paltiel of the Hebrew University of Jerusalem and Ron Naaman from the Weizmann Institute of Science describes a breakthrough technology with the power to create drugs with fewer unwanted side effects.
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018